Amarin Corp Plc (AMRN)

[Biobillionair]

What indication did Amarin ask for?

This document claims we will be discussing Anchor, combination use ie. AMR 102, and treatment of CV disease. Anchor 200-500 is not specifically mentioned.


Docket # FDA 2013 N 0001

General Function of the meeting:
To provide advice and recommendations to the Agency on FDA's regulatory issues.

Agenda: To discuss the supplemental new drug application 202057/S-005

This supplemental ap proposes concomitant use with an inhibitor of HMG-CoA to reduce trigs, non HDL, APO B, LDL, very low LDL in mixed dys, CHD, or
CHD risk equivalent.
----------

What exactly is the FDA up to here?